FDA Approved: KESIMPTA — Original Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

The FDA approved Kesimpta (ofatumumab) under an original Biologics License Application from Novartis for the treatment of relapsing forms of multiple sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Kesimpta (ofatumumab)

Snippet

ORIG AP for KESIMPTA (OFATUMUMAB)